Modelling time-kill studies to discern the pharmacodynamics of meropenem

Journal of Antimicrobial Chemotherapy

Volumn 55, Issue 5, 2005, Pages 699-706

  Tam, Vincent H ^a   Schilling, Amy N ^a   Nikolaou, Michael ^b  

^a UNIVERSITY OF HOUSTON   (United States)

^b University of Houston   (United States)

Author keywords

Mathematical models; Pharmacodynamics modelling; Pseudomonas aeruginosa

Indexed keywords

MEROPENEM;

ADAPTATION; ANIMAL CELL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BAYES THEOREM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DATA ANALYSIS; GROWTH RATE; MATHEMATICAL MODEL; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NONPARAMETRIC TEST; PREDICTION; PROBABILITY; PSEUDOMONAS AERUGINOSA; QUANTITATIVE ANALYSIS; TIME;

ANTI-BACTERIAL AGENTS; COLONY COUNT, MICROBIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; PSEUDOMONAS AERUGINOSA; THIENAMYCINS;

EID: 18844410491     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dki086     Document Type: Article

References (28)

1. Mouton, J. W., Vinks, A. A. & Punt, N. C. (1997). Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion. Antimicrobial Agents and Chemotherapy 41, 733-8.
2. Jumbe, N., Louie, A., Leary, R. et al. (2003). Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. Journal of Clinical Investigation 112, 275-85.
3. Tam, V. H., Louie, A., Deziel, M. R., et al. (2001). Prevention of emergence of resistance of Pseudomonas aeruginosa (PA) through population co-modeling drug concentration, susceptible and resistant populations (P) In Programs and Abstracts of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2001, Abstract A-2100, p. 35. American Society for Microbiology, Washington, DC, USA.
4. Livermore, D. M. (2002). Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clinical Infectious Diseases 34, 634-40.
5. Gales, A. C., Sader, H. H. & Jones, R. N. (2002). Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia in Latin America: frequency of occurrence and antimicrobial susceptibility profile: results from the SENTRY Antimicrobial Surveillance Program (1997-2000). Diagnostic Microbiology and Infectious Diseases 44, 301-11.
6. Neuhauser, M. M., Weinstein, R. A., Rydman, R. et al. (2003). Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. Journal of the American Medical Association 289, 885-8.
7. Landman, D., Quale, J. M., Mayorga, D. et al. (2002). Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: the preantibiotic era has returned. Archives of Internal Medicine 162, 1515-20.
8. National Committee for Clinical Laboratory Standards (2003). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Sixth Edition M7-A6 NCCLS, Villanova, PA, USA.
9. Zhi, J., Nightingale, C. H. & Quintiliani, R. (1986). A pharmacodynamic model for the activity of antibiotics against microorganisms under nonsaturable conditions. Journal of Pharmaceutical Sciences 75, 1063-7.
10. Zhi, J. G., Nightingale, C. H. & Quintiliani, R. (1988). Microbial pharmacodynamics of piperacillin in neutropenic mice of systematic infection due to Pseudomonas aeruginosa. Journal of Pharmacokinetics and Biopharmaceutics 16, 355-75.
11. Leary, R., Jelliffe, R., Schumitzky, A., et al. (2001). An adaptive grid non-parametric approach to pharmacokinetic and dynamic (PK/PD) models. In Fourteenth IEEE Symposium on Computer-Based Medical Systems, Bethesda, MD, 2001, pp. 289-394. IEEE Computer Society, Washington, DC, USA.
12. D'Argenio, D. Z. & Schumitzky, A. (1997), Biomedical simulations resource ADAPT II User's Guide: Pharmacokinetic/Pharmacodynamic Systems Analysis Software. Biomedical simulations resource, University of Southern California, Los Angeles, CA, USA.
13. Craig, W. A. & Ebert, S. C. (1990). Killing and regrowth of bacteria in vitro: a review. Scandinavian Journal of Infectious Diseases Supplement 74, 63-70.
14. Miyazaki, S., Okazaki, K., Tsuji, M. et al. (2004). Pharmacodynamics of S-3578, a novel cephem, in murine lung and systemic infection models. Antimicrobial Agents and Chemotherapy 48, 378-83.
15. Andes, D., Marchillo, K., Conklin, R. et al. (2004). Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis. Antimicrobial Agents and Chemotherapy 48, 137-42.
16. Maglio, D., Ong, C., Banevicius, M. A. et al. (2004). Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-β-lactamase-producing Escherichia coli at various inocula. Antimicrobial Agents and Chemotherapy 48, 1941-7.
17. Dandekar, P. K., Tessier, P. R., Williams, P. et al. (2003). Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model. Journal of Antimicrobial Chemotherapy 52, 405-11.
18. Lipsitch, M. & Levin, B. R. (1997). The population dynamics of antimicrobial chemotherapy. Antimicrobial Agents and Chemotherapy 41, 363-73.
19. Regoes, R. R., Wiuff, C., Zappala, R. M. et al. (2004). Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens. Antimicrobial Agents and Chemotherapy 48, 3670-6.
20. Fredrickson, A. G. (1977). Behavior of mixed cultures of microorganisms. Annual Reviews of Microbiology 31, 63-87.
21. Mueller, M., de la Pena, A. & Derendorf, H. (2004). Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC. Antimicrobial Agents and Chemotherapy 48, 369-77.
22. Tam, V. H., Louie, A., Deziel, M. R., et al. (2001). AUC/MIC ratio and duration of therapy both influence the probability of emergence of resistance to a fluoroquinolone in an in vitro hollow fiber infection model (IVHFIM). In Programs and Abstracts of the Thirty-ninth Annual Meeting of the Infectious Diseases Society of America, San Francisco, CA, 2001, Abstract 473, p. 1169. Infectious Diseases Society of America, Alexandria, VA, USA.
23. Lawrence, J., Mayers, D. L., Hullsiek, K. H. et al. (2003). Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. New England Journal of Medicine 349, 837-46.
24. Tam, V. H., Schilling, A. N., Lewis, R. E., et al. (2004). Novel approach to characterization of combined pharmacodynamic effects of antimicrobial agents. Antimicrobial Agents and Chemotherapy 48, 4315-21.
25. Bonhoeffer, S., Lipsitch, M. & Levin, B. R. (1997). Evaluating treatment protocols to prevent antibiotic resistance. Proceedings of the National Academy of Sciences, USA 94, 12106-11.
26. Drusano, G. L. (2004). Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nature Review Microbiology 2, 289-300.
27. Lipsitch, M., Bacon, T. H., Leary, J. J. et al. (2000). Effects of antiviral usage on transmission dynamics of herpes simplex virus type 1 and on antiviral resistance: predictions of mathematical models. Antimicrobial Agents and Chemotherapy 44, 2824-35.
28. Webb, G. F. & Blaser, M. J. (2002). Dynamics of bacterial phenotype selection in a colonized host. Proceedings of the National Academy of Sciences, USA 99, 3135-40.